2652 CF PharmTech, Inc. HKEX · China

CF PharmTech (2652) news

CF PharmTech, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2652, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CF PharmTech news

We have not published a story on CF PharmTech yet. When there is news, it will appear here.

Questions about CF PharmTech

What is the ticker symbol of CF PharmTech?

CF PharmTech, Inc. trades under the ticker 2652 on HKEX.

Where is CF PharmTech listed?

CF PharmTech, Inc. is listed on HKEX.

Which country or territory is CF PharmTech listed under?

Our directory records CF PharmTech, Inc. under China.

What does CF PharmTech do?

Our directory classifies CF PharmTech, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of CF PharmTech?

The ISIN recorded for CF PharmTech, Inc. is CNE1000074R9.

Does aibio.space cover CF PharmTech?

aibio.space lists CF PharmTech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to CF PharmTech?

Companies in our directory listed in the same country and business area as CF PharmTech: Enwei Pharmaceutical Co., Yili Chuanning Biotechnology Co., ApicHope Pharmaceutical Group Co., Zhejiang Hisun Pharmaceutical Co., Zhuhai Rundu Pharmaceutical Co., Fusen Pharmaceutical Co..

Investor discussion: CF PharmTech

Members talk about CF PharmTech (2652). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CF PharmTech, newest first. Each line links the filing it comes from.

Aug 6, 2026Financings
Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Jul 30, 2026Financings
Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source
Jun 22, 2026Listings
Share consolidation: CHANGE IN BOARD LOT SIZE. Source
Jun 2, 2026Financings
Share or debt issue: (1) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025; (2) 2025 ANNUAL REPORT; (3) ELECTION OF THE FOURTH SESSION OF THE BOARD; (4) ELECTION OF THE FOURTH SESSION OF THE SUPERVISORY COMMITTEE; (5) RE-APPOINTMENT OF AUDITOR FOR 2026; (6) PROPOSED AMENDMENTS TO THE H SHARE AWARD SCHEME; (7) GENERAL MANDATE TO ISSUE H SHARES; (8) SHARE REPURCHASE MANDATE TO REPURCHASE H SHARES; AND (9) NOTICE OF ANNUAL GENERAL MEETING. Source
Nov 26, 2025Financings
Share or debt issue: PROPOSED SHARE REPURCHASE MANDATE PROPOSED ADOPTION OF H SHARE AWARD SCHEME PROPOSED AUTHORIZATION TO THE BOARD AND/OR AUTHORIZED PERSON TO HANDLE MATTERS RELATING TO THE H SHARE AWARD SCHEME AND NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING. Source
Sep 25, 2025Financings
Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of CF PharmTech's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 5, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT VOLUNTARY EXTENSION OF LOCK-UP PERIOD FOR SHARES HELD BY CORE MANAGEMENT BY SIX MONTHS
Sep 21, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ICF004 COMPLETES ENROLMENT AND DOSING OF FIRST HEALTHY VOLUNTEER IN PHASE I CLINICAL TRIAL
Aug 31, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Aug 28, 2026HKEXnews
Articles of Association
Aug 24, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT EXPANSION OF INDICATIONS OF ICF001 FOLLOWING RECEIPT OF IMPLIED CLINICAL TRIAL APPROVALS FROM THE NMPA
Aug 6, 2026HKEXnews
COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Jul 30, 2026HKEXnews
PLACING OF NEW H SHARES UNDER GENERAL MANDATE
Jun 26, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026; ELECTION OF THE FOURTH SESSION OF THE BOARD; AND ELECTION OF THE FOURTH SESSION OF THE SUPERVISORY COMMITTEE
Jun 22, 2026HKEXnews
CHANGE IN BOARD LOT SIZE
Jun 4, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT INHALATION FORMULATION PRODUCTION BASE PASSED GMP INSPECTION IN A PIC/S MEMBER COUNTRY
Jun 2, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jun 2, 2026HKEXnews
(1) AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR 2025; (2) 2025 ANNUAL REPORT; (3) ELECTION OF THE FOURTH SESSION OF THE BOARD; (4) ELECTION OF THE FOURTH SESSION OF THE SUPERVISORY COMMITTEE; (5) RE-APPOINTMENT OF AUDITOR FOR 2026; (6) PROPOSED AMENDMENTS TO THE H SHARE AWARD SCHEME; (7) GENERAL MANDATE TO ISSUE H SHARES; (8) SHARE REPURCHASE MANDATE TO REPURCHASE H SHARES; AND (9) NOTICE OF ANNUAL GENERAL MEETING
Jun 1, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT IND APPROVAL OF ICF004 AS A CLASS 1 NEW DRUG BY THE NMPA
May 29, 2026HKEXnews
RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND A SUPERVISOR; AND PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR AND A SUPERVISOR
May 28, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT SUBMISSION OF MARKETING AUTHORIZATION APPLICATION FOR CF017 IN A SOUTHEAST ASIAN MARKET
May 26, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR TIOTROPIUM BROMIDE INHALATION POWDER BY THE NMPA
Mar 30, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Mar 23, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION WITH JD HEALTH
Mar 20, 2026HKEXnews
INSIDE INFORMATION PROFIT WARNING
Mar 13, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF IND APPLICATION FOR ICF001 BY THE NMPA

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2652 on TradingView.

Listing details

Company: CF PharmTech, Inc.
Ticker: 2652
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: CNE1000074R9
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction